The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The following is a summary of "A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... paired triplet misses survival mark in kidney cancer, Exelixis shifts ...

Overall survival (OS) data were not mature ... Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer ...

About one-sixth of neuroendocrine tumors are classified by pathologists as high grade. Survival rates from high-grade cancer vary with the site of disease, but most patients succumb within a year ...

The American Cancer Society’s Colleges Against Cancer program at Shippensburg University hosted its annual Relay for Life ...

Results of study directed by Rodrigo Toledo, Head of the Vall d'Hebron Institute of Oncology's (VHIO) Biomarkers and Clonal ...